Ocular side effects due to these ergot alkaloids are rare, but patients on standard therapeutic dosages can develop significant adverse ocular effects. This is probably due to an unusual susceptibility, sensitivity or pre-existing disease that is exacerbated by the ergot preparations. Increased ocular vascular complications have been seen in patients with a preexisting occlusive peripheral vascular disease, especially in dosages higher than normal. Crews (1963) reported a healthy 19 year old in whom a standard therapeutic injection of ergotamine apparently precipitated a central retinal artery occlusion. Borooah et al (2008) reported a prolonged cilioretinal artery spasm leading to a permanent retinal disturbance in a 31-year-old postpartum patient after receiving ergometrine during delivery. Gupta et al (1972) reported a bilateral ischemic optic neuritis that may have been due to ergotamine. Merhoff et al (1974) reported a case with possible drug-induced central scotoma, retinal vasospasms and retinal pallor. Heider et al (1986) reported the case of a long-term ergot user who developed reversible decreased vision with decreased sensitivity in the central 30 ° in his visual field. Sommer et al (1998) described a 31-year-old male who developed bilateral ischemic optic neuropathy after administration of ergotamine tartrate and macrolides. Mieler (1997) reported a 19-year-old female who received ergot alkaloids to control postpartum hemorrhage and had a toxic retinal reaction, including bilateral cystoid macular edema, central retinal vein occlusion papillitis and optic disc pallor. Ahmad (1991) described a case of ergometrine given intravenously that unmasked a previously “cured” myasthenia gravis. According to Creze et al (1976) methylergometrine-induced cerebral vasospasm may have caused transitory cortical blindness. There are sporadic reports of cataracts in the literature, but these are rare and it is difficult to prove a cause-and-effect relationship.